Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 1;19(2):2251825.
doi: 10.1080/21645515.2023.2251825.

Real-world impact and effectiveness of MenACWY-TT

Rodolfo Villena  1   2 , Paula Kriz  3 , Myint Tin Tin Htar  4 , Cindy Burman  5 , Jamie Findlow  6 , Paul Balmer  5 , Luis Jodar  5
Affiliations
Review

Real-world impact and effectiveness of MenACWY-TT

Rodolfo Villena et al. Hum Vaccin Immunother. .

Abstract

In response to escalating cases of serogroup W (MenW) invasive meningococcal disease (IMD), multiple countries introduced quadrivalent conjugate MenACWY vaccines into their national immunization programs (NIPs). Here, we summarize the real-world impact and vaccine effectiveness (VE) data of MenACWY-TT from Chile, England, the Netherlands, and Australia. Incidence rate reductions (IRRs) and VE from baseline to post-NIP period were extracted from publications or calculated. After the administration of a single dose of MenACWY-TT, substantial IRRs of MenCWY were observed across the countries in vaccine-eligible age groups (83%-85%) and via indirect protection in non-vaccine-eligible age groups (45%-53%). The impact of MenACWY-TT was primarily driven by MenW IRRs, as seen in vaccine-eligible age groups (65%-92%) and non-vaccine-eligible age groups (41%-57%). VE against MenW was reported in vaccine-eligible toddlers (92%) in the Netherlands and in vaccine-eligible adolescents/young adults (94%) in England. These real-world data support the implementation and continued use of MenACWY-TT in NIPs.

Keywords: Invasive meningococcal disease; MenACWY-TT; meningococcal vaccine; vaccine effectiveness; vaccine impact.

PubMed Disclaimer

Conflict of interest statement

R. Villena reports a relationship with Pfizer, GSK, Sanofi Pasteur and Janssen that includes consulting or advisory and speaking and lecture fees. M. Tin Tin Htar, C. Burman, J. Findlow, P. Balmer, and L. Jodar are employees of Pfizer Inc. and may hold company shares. P. Kriz reports no conflicts.

Figures

Figure 1.
Figure 1.
Incidence rate reductions (95% CI) against MenW and MenCWY disease following the introduction of MenACWY vaccination programs among vaccine-eligible age groups.
Figure 2.
Figure 2.
Incidence rate reductions (95% CI) against MenW and MenCWY disease following the introduction of MenACWY vaccination programs among non-vaccine-eligible age groups and the entire population.
See this image and copyright information in PMC

References

    1. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. doi:10.1186/1478-7954-11-17. - DOI - PMC - PubMed
    1. Harrison LH, Trotter CL, Ramsay ME.. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–8. doi:10.1016/j.vaccine.2009.04.063. - DOI - PubMed
    1. Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30(Suppl 2):B10–7. doi:10.1016/j.vaccine.2011.12.060. - DOI - PubMed
    1. WHO . WHO vaccine-preventable diseases: monitoring system. 2020 global summary. [accessed 2022 Jan 27]. https://apps.who.int/immunization_monitoring/globalsummary/schedules.
    1. Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJM, Pollard AJ, Turner DPJ, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–31. doi:10.1016/S0140-6736(14)60842-4. - DOI - PubMed

Publication types

Substances